SCHEMBL105486

Kakonein is a lipid of Polyketides (PK) class. Kakonein is associated with abnormalities such as Fatty Liver, Chronic liver disease, Morphologically altered structure, Hypertensive disease and Cardiovascular Diseases. The involved functions are known as protein expression, Extravasation, Liver damage, mRNA Expression and cell activation. Kakonein often locates in Body tissue, Hepatic, Microvilli, Cytoplasm and Membrane. The associated genes with Kakonein are TJP1 gene, CD14 gene, iberiotoxin, AT-Rich Interactive Domain-Containing Protein 1A and NKS1 gene. The related lipids are dehydrosoyasaponin I and Steroids. The related experimental models are Knock-out.

Cross Reference

Introduction

To understand associated biological information of SCHEMBL105486, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with SCHEMBL105486?

SCHEMBL105486 is suspected in Chronic liver disease, Hypertensive disease, Cardiovascular Diseases, Myocardial Infarction, Cerebrovascular accident, Fatty Liver and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with SCHEMBL105486

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Lead Poisoning D007855 4 associated lipids
Adenocarcinoma D000230 166 associated lipids
Burns D002056 34 associated lipids
Inflammation D007249 119 associated lipids
Reperfusion Injury D015427 65 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Diabetic Nephropathies D003928 39 associated lipids
Fatty Liver D005234 48 associated lipids
Per page 10 20 50 | Total 43

PubChem Associated disorders and diseases

What pathways are associated with SCHEMBL105486

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with SCHEMBL105486?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with SCHEMBL105486?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with SCHEMBL105486?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with SCHEMBL105486?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with SCHEMBL105486?

Knock-out

Knock-out are used in the study 'MATE2 mediates vacuolar sequestration of flavonoid glycosides and glycoside malonates in Medicago truncatula.' (Zhao J et al., 2011).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with SCHEMBL105486

Download all related citations
Per page 10 20 50 100 | Total 919
Authors Title Published Journal PubMed Link
Bacanlı M et al. The antioxidant, cytotoxic, and antigenotoxic effects of galangin, puerarin, and ursolic acid in mammalian cells. 2017 Drug Chem Toxicol pmid:27461151
Wu L et al. Protective Effects of Puerarin against Aβ 1-42-Induced Learning and Memory Impairments in Mice. 2017 Planta Med. pmid:27420352
Kim Y et al. Pharmacokinetics and Safety of DW1029M, a Botanical Drug for the Treatment of Diabetic Nephropathy, Following Single Doses in Healthy Subjects. 2017 Clin Pharmacol Drug Dev pmid:28301092
Li P et al. In Vivo Pharmacokinetics of Puerarin via Different Drug Administration Routes Based on Middle Cerebral Artery Occlusion Model. 2017 Eur J Drug Metab Pharmacokinet pmid:27928655
Wang L et al. Puerarin Enhances Ca2+ Reuptake and Ca2+ Content of Sarcoplasmic Reticulum in Murine Embryonic Stem Cell-Derived Cardiomyocytes via Upregulation of SERCA2a. 2017 Cell. Physiol. Biochem. pmid:29179218
Wang J et al. Novel cationic lipid nanoparticles as an ophthalmic delivery system for multicomponent drugs: development, characterization, in vitro permeation, in vivo pharmacokinetic, and molecular dynamics studies. 2017 Int J Nanomedicine pmid:29158673
Lin L et al. The Effects and Possible Mechanisms of Puerarin to Treat Uterine Fibrosis Induced by Ischemia-Reperfusion Injury in Rats. 2017 Med. Sci. Monit. pmid:28704345
Shang Z et al. Rapid profiling and identification of puerarin metabolites in rat urine and plasma after oral administration by UHPLC-LTQ-Orbitrap mass spectrometer. 2017 J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. pmid:29073480
Deng HF et al. Puerarin inhibits expression of tissue factor induced by oxidative low-density lipoprotein through activating the PI3K/Akt/eNOS pathway and inhibiting activation of ERK1/2 and NF-κB. 2017 Life Sci. pmid:29037842
Tan C et al. Puerarin Improves Vascular Insulin Resistance and Cardiovascular Remodeling in Salt-Sensitive Hypertension. 2017 Am. J. Chin. Med. pmid:28830209